Claims:

1. A method of detecting breast cancer or lung cancer in a patient comprising the steps of:

a) Measuring an amount of a polypeptide of SEQ ID No. 1 with a phosphorylated tyrosine at Y192 in a first cell sample isolated from the patient; and

b) Comparing the amount of polypeptide of SEQ ID No. 1 with a phosphorylated tyrosine at Y192 in the cell sample to an amount of polypeptide of SEQ ID No. 1 with a phosphorylated tyrosine at Y192 in a second cell sample isolated from normal, non-cancerous cells,

wherein an amplified amount of polypeptide of SEQ ID No. 1 with a phosphorylated tyrosine at Y192 in the first cell sample relative to the amount of polypeptide of SEQ ID No. 1 with a phosphorylated tyrosine at Y192 in the second cell sample indicates breast cancer or lung cancer is present in the first cell sample.

2. The method of claim 1 further comprising measuring the amount of the polypeptide of SEQ ID No. 1 with a phosphorylated tyrosine at Y231 in the first and second cell sample wherein an amplified amount of polypeptide of SEQ ID No. 1 with a phosphorylated tyrosine at Y192 and Y231 in the first cell sample relative to the amount of polypeptide of SEQ ID No. 1 with a phosphorylated tyrosine at Y192 and Y231 in the second cell sample indicates cancer is present in the first cell sample.

3. The method of claim 1 or 2 whereby the cancer is dependent on EGFR, c-Src, c-Yes, ER, Wnt, WBP2 or E2F.

4. The method of any one of claims 1 to 3 whereby the amount of the polypeptide of SEQ ID No. 1 with a phosphorylated tyrosine is measured with an isolated phosphorylation site-specific antibody that specifically binds to a WW-domain binding protein of SEQ ID. NO. 1 only when the polypeptide is phosphorylated at the tyrosine Y192 or the tyrosine Y192 and the tyrosine Y231 wherein the antibody does not bind the polypeptide of SEQ ID No. 1 when it is not phosphorylated at said tyrosine.

5. The method of any one of claims 1 to 3 further comprising the steps of:

c) bringing the polypeptide of SEQ ID No. 1 into contact with a polynucleotide probe or primer comprising a polynucleotide sequence capable of hybridising selectively to the polypeptide of SEQ ID No. 1 only when the polypeptide is phosphorylated at the tyrosine Y192 or the tyrosine Y192 and the tyrosine Y231 under suitable hybridising conditions; and

d) detecting any duplex formed between the probe or primer and the polypeptide of SEQ ID No. 1 phosphorylated at said tyrosine.

6. The method of any one of claims 1 to 3 whereby the amount of the polypeptide of SEQ ID No. 1 with a phosphorylated tyrosine is measured with an isolated phosphorylation site-specific aptamers that specifically binds to a WW-domain binding protein of SEQ ID. NO. 1 only when the polypeptide is phosphorylated at the tyrosine Y192 or Y231 or the tyrosine Y192 and the tyrosine Y231 wherein the aptamers does not bind the polypeptide of SEQ ID No. 1 when it is not phosphorylated at said tyrosine.

7. The method of any one of claims 1 to 6 whereby the first and second cell sample are isolated from a nuclear fraction of the cell.

8. An agent to block phosphorylation of tyrosine Y192 and Y231 in the polypeptide of SEQ ID NO. 1, wherein the agent is a vector capable of overexpressing a peptide including tyrosine sites Y192 and Y231 or a phosphorylation-defective polypeptide of SEQ ID. NO. 1 that includes a mutation at the tyrosine Y192 and Y231.

9. The agent of claim 8 wherein the peptide comprises SEQ ID. NO. 5; or SEQ ID. NO. 6 and a nuclear localization signal.

10. The agent of claim 8 wherein said phosphorylation-defective polypeptide of SEQ ID. NO. 1 includes a mutation of the tyrosine Y192 and Y231 to phenylalanine.

11. A cell line producing an agent of any one of claims 8 to 10.


12. The agent of any one of claims 8 to 10 for use in the treatment of breast cancer.

13. The agent of claim 12 whereby the cancer is dependent on EGFR, c-Src, c-Yes, ER, Wnt, WBP2 or E2F.


14. The agent of claim 10 further comprising a TCF/β-catenin inhibitor, anti-EGFR, anti-src, anti-c-Yes, anti-E2F, or anti-ERα compounds.

15. A composition comprising the agent of claim 10 and a TCF/β-catenin inhibitor or an anti-estrogen receptor α compound for use in the treatment of breast cancer.

16. The agent of claim 14 or the composition of claim 15 wherein the TCF/β-catenin inhibitor is an FH535 of formula 1



17. The agent of claim 14 or the composition of claim 15 wherein the anti-estrogen receptor α compound is a Fulvestrant of formula 2




18. Use of an agent according to claim 10 in preparation of a medicament for the treatment of breast cancer.

19. Use of a composition comprising:

an agent according to claim 10; and

a TCF/ β-catenin inhibitor or an anti-estrogen receptor α compound in preparation of a medicament for the treatment of breast cancer.

20. The use of claim 19 wherein the TCF/β-catenin inhibitor is an FH535 of formula 1



21. The use of claim 19 wherein the anti-estrogen receptor-α compound is a Fulvestrant of formula 2

